SFU
PCRX icon

Stonehage Fleming (UK)’s Pacira BioSciences PCRX Stock Holding History

Stonehage Fleming (UK)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-413
Closed -$37K – 245
2014
Q4 		$37K Buy
413
+165
+67% +$15.6K 0.02% 189
2014
Q3 		$24K Sell
248
-8
-3% -$778 0.01% 237
2014
Q2 		$24K Buy
+256
New +$19.5K 0.01% 227

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stonehage Fleming (UK)'s PCRX Position: Q1 2015 in Review

Stonehage Fleming (UK) sold out of Pacira BioSciences (PCRX) in Q1 2015, closing a stake of 413 shares — an estimated $37K sold.

Stonehage Fleming (UK) first reported a position in PCRX in Q2 2014 and held it in 3 quarters. The position peaked at $37K in Q4 2014. 205 funds tracked by Wall St. Rank hold PCRX as of Q1 2015.

  • Stonehage Fleming (UK) reported no remaining Pacira BioSciences position as of Q1 2015 after selling out during the quarter.
  • Stonehage Fleming (UK) sold 413 Pacira BioSciences shares in Q1 2015, an estimated $37K.
  • Stonehage Fleming (UK) first reported a position in Pacira BioSciences in Q2 2014 and held it in 3 quarters.
  • Stonehage Fleming (UK)'s Pacira BioSciences position peaked at $37K in Q4 2014.
  • 205 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2015.

Based on Stonehage Fleming (UK)'s 13F filing for Q1 2015, filed 11 Oct 2019.